What Is the Best GLP-1 Supplement for Weight Loss? Industry Analysis Reveals Probiotic Akkermansia Formulas as Affordable Ozempic Alternatives 
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial...
NEXGEL Launches Turfguard to Treat Painful Turf Burns and Protect Sports-Related Wounds
LANGHORNE, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (NASDAQ: NXGL, NXGLW), (“NEXGEL” or the “Company”), a leading provider...
Cytokinetics Presents Data at the Virtual 33rd International Symposium on ALS/MND
Analysis from FORTITUDE-ALS Shows Predicted Survival Risk Score Strongly Correlated with Decline in ALSFRS-R Findings Suggest Inclusion Criteria for COURAGE-ALS Will...
Jushi Holdings Inc. Announces Closing of US$69 Million Debt Financing
Additional US$5 million in Subscriptions to Close at a Later DateBOCA RATON, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Jushi...
Sensei Biotherapeutics Provides Update on Strategic Priorities
- Closes Boston research site, reducing workforce by approximately 40 percent to decrease operating expenses -- Continued focus on development...
The Joint Corp. to Participate in the 11th Annual ROTH Deer Valley Event
SCOTTSDALE, Ariz., Dec. 08, 2022 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of...
Microbot Medical’s Proprietary LIBERTY® Robotic System Receives Third Patent Allowance in Israel
Pace of Jurisdictional Allowances Parallels Pre-Clinical and Regulatory ProgressHINGHAM, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:...
Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings
TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual...
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance...
XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Independent Study Shows Moderate Dose Strength of XORLO™ Attenuates Kidney ExpansionCALGARY, Alberta, Dec. 08, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics...
Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
BOSTON, MASSACHUSETTS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral...
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
Discontinuing unmodified TIL programs, including DELTA-1 and DELTA-2 trials of ITIL-168Prioritizing CoStAR-TIL programs for clinical development, including ITIL-306 in Phase...
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
Phase 2 clinical trial initiation expected in 2023Company to host conference call to discuss recent clinical updates, including updated data...
Cabaletta Bio Announces $35 Million Offering
PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company...
Asensus Announces Additional Senhance Surgical System Sale
Oncology focused hospital to initiate Senhance System programRESEARCH TRIANGLE PARK, N.C., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc....
Pharvaris Reports Third Quarter 2022 Financial Results and Provides Business Update
Announced positive top-line data for RAPIDe-1, a global Phase 2 study of PHVS416 for the on-demand treatment of HAE attacksParticipated...
Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks
Primary endpoint met, substantially reducing HAE attack symptomsAll secondary endpoints metPHVS416 was well tolerated at all dose levelsPharvaris to host...
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4 Phase 1 trial enrolled all comers, with vast...
RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer
Data Presented at ESMO Immuno-Oncology CongressSOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT),...
Rentschler implements innovative learning program in collaboration with MassBioEd and WPI
Program trains people returning to the workforce for biotech manufacturing positionsLAUPHEIM, Germany and MILFORD, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE)...